Vor Biopharma (NASDAQ:VOR) Major Shareholder Sells $1,567,709.88 in Stock

Vor Biopharma Inc. (NASDAQ:VOR) major shareholder Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $32.07, for a total value of $1,567,709.88. Following the completion of the transaction, the insider owned 1,374,775 shares in the company, valued at $44,089,034.25. This represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Wednesday, October 8th, Reprogrammed Interchange Llc sold 75,262 shares of Vor Biopharma stock. The stock was sold at an average price of $33.87, for a total value of $2,549,123.94.
• On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The shares were sold at an average price of $33.84, for a total value of $934,796.16.
• On Monday, October 6th, Reprogrammed Interchange Llc sold 70,763 shares of Vor Biopharma stock. The shares were sold at an average price of $37.01, for a total transaction of $2,618,938.63.
• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The shares were sold at an average price of $37.83, for a total transaction of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The stock was sold at an average price of $39.83, for a total transaction of $1,292,523.33.
• On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The stock was sold at an average price of $39.19, for a total transaction of $54,866.00.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The shares were sold at an average price of $1.54, for a total transaction of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The shares were sold at an average price of $30.80, for a total transaction of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $32.80, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The shares were sold at an average price of $35.00, for a total value of $525,000.00.

Vor Biopharma Price Performance

Vor Biopharma stock opened at $31.23 on Monday. Vor Biopharma Inc. has a 1-year low of $2.62 and a 1-year high of $65.80. The stock has a fifty day simple moving average of $37.73. The firm has a market cap of $214.05 million, a PE ratio of -0.11 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts’ consensus estimates of ($11.40) by ($32.20).

Hedge Funds Weigh In On Vor Biopharma

Several institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Investments LP raised its holdings in Vor Biopharma by 18.9% in the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock worth $181,000 after purchasing an additional 25,930 shares during the period. Money Concepts Capital Corp increased its position in shares of Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after buying an additional 26,535 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new position in shares of Vor Biopharma during the 1st quarter worth approximately $100,000. Goldman Sachs Group Inc. lifted its position in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in Vor Biopharma in the 1st quarter valued at $140,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Wall Street Analysts Forecast Growth

VOR has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of Vor Biopharma to a “strong sell” rating in a research note on Saturday, June 28th. Zacks Research raised shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 10th. Wedbush restated an “outperform” rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Stifel Nicolaus raised Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research report on Wednesday, September 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Vor Biopharma in a report on Thursday, August 14th. Five research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Vor Biopharma has an average rating of “Hold” and a consensus target price of $113.83.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.